First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) Trading 0.6% Higher – Here’s Why

First Trust Nasdaq Pharmaceuticals ETF (NASDAQ:FTXH) was up 0.6% during trading on Monday . The stock traded as high as $33.91 and last traded at $33.94. Approximately 1,276 shares were traded during mid-day trading, a decline of 70% from the average daily volume of 4,292 shares. The stock had previously closed at $33.73.

First Trust Nasdaq Pharmaceuticals ETF Price Performance

The company has a market capitalization of $22.06 million, a price-to-earnings ratio of 14.51 and a beta of 0.54. The firm’s 50-day simple moving average is $33.00 and its two-hundred day simple moving average is $29.91.

First Trust Nasdaq Pharmaceuticals ETF Cuts Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, December 31st. Investors of record on Friday, December 12th were issued a $0.1294 dividend. The ex-dividend date was Friday, December 12th. This represents a $0.52 dividend on an annualized basis and a dividend yield of 1.5%.

Institutional Trading of First Trust Nasdaq Pharmaceuticals ETF

A number of institutional investors have recently bought and sold shares of FTXH. Goldman Sachs Group Inc. grew its holdings in First Trust Nasdaq Pharmaceuticals ETF by 11.7% in the first quarter. Goldman Sachs Group Inc. now owns 19,472 shares of the company’s stock valued at $535,000 after purchasing an additional 2,047 shares during the last quarter. Envestnet Asset Management Inc. boosted its position in shares of First Trust Nasdaq Pharmaceuticals ETF by 2.1% in the 3rd quarter. Envestnet Asset Management Inc. now owns 18,132 shares of the company’s stock worth $517,000 after buying an additional 367 shares in the last quarter. Ameritas Investment Partners Inc. grew its stake in First Trust Nasdaq Pharmaceuticals ETF by 9.7% in the 3rd quarter. Ameritas Investment Partners Inc. now owns 17,232 shares of the company’s stock valued at $491,000 after acquiring an additional 1,521 shares during the last quarter. Summit Investment Advisors Inc. increased its holdings in First Trust Nasdaq Pharmaceuticals ETF by 8.1% during the 1st quarter. Summit Investment Advisors Inc. now owns 15,320 shares of the company’s stock valued at $421,000 after acquiring an additional 1,147 shares in the last quarter. Finally, Vivaldi Capital Management LP increased its holdings in First Trust Nasdaq Pharmaceuticals ETF by 4.1% during the 3rd quarter. Vivaldi Capital Management LP now owns 9,790 shares of the company’s stock valued at $279,000 after acquiring an additional 384 shares in the last quarter.

First Trust Nasdaq Pharmaceuticals ETF Company Profile

The First Trust Nasdaq Pharmaceuticals ETF (FTXH) is an exchange-traded fund that is based on the Nasdaq US Smart Pharmaceuticals index. The fund tracks the 30 most liquid US pharmaceutical companies, weighted according to factors related to value, volatility, and growth. FTXH was launched on Sep 20, 2016 and is managed by First Trust.